Preferred Label : enzalutamide;
MeSH note : an antineoplastic agent;
CISMeF synonym : MDV 3100;
MeSH synonym : 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide;
MeSH hyponym : HC-1119; HC 1119; 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; MDV3100; MDV-3100;
MeSH Related Number : 3OKI556HC2;
Is substance : O;
UNII : 93T0T9GKNU;
Origin ID : C540278;
UMLS CUI : C3496793;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/enzalutamide-viatris
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
enzalutamide
enzalutamide
drugs, generic
---
https://www.has-sante.fr/jcms/p_3420592/fr/xtandi-enzalutamide-cancer-de-la-prostate-metastatique-hormonosensible-mhspc
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
neoplasm metastasis
Hormone sensitive prostate cancer (disorder)
adult
antineoplastic combined chemotherapy protocols
antineoplastic agents, hormonal
enzalutamide
evaluation of the transparency committee
prostatic neoplasms
enzalutamide
---
https://ansm.sante.fr/tableau-atu-rtu/xtandi-40-mg-comprime-pellicule
2021
false
true
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
administration, oral
enzalutamide
prostatic neoplasms
neoplasms, hormone-dependent
neoplasm metastasis
adult
antineoplastic agents, hormonal
enzalutamide
phenylthiohydantoin
phenylthiohydantoin
---
https://www.has-sante.fr/jcms/p_3284790/fr/xtandi-40-mg-enzalutamide
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
enzalutamide
prostatic neoplasms
neoplasms, hormone-dependent
neoplasm metastasis
antineoplastic combined chemotherapy protocols
antineoplastic agents, hormonal
enzalutamide
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/pprd_2983149/fr/xtandi
https://www.has-sante.fr/jcms/p_3069202/fr/xtandi
2019
false
true
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
adult
prostatic neoplasms, Castration-Resistant
enzalutamide
antineoplastic agents, hormonal
androgen antagonists
enzalutamide
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3076390
2019
false
false
false
France
evaluation of the transparency committee
enzalutamide
enzalutamide
enzalutamide
---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Hormonotherapie-enzalutamide
2019
false
false
false
France
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
continuity of patient care
risk factors
patient education as topic
prostatic neoplasms, Castration-Resistant
enzalutamide
androgen antagonists
androgen receptor antagonists
antineoplastic agents, hormonal
antineoplastic agents, hormonal
administration, oral
neoplasm metastasis
Common Terminology Criteria for Adverse Events
hypertension
long qt syndrome
seizures
headache disorders
fatigue
leukopenia
neutropenia
thrombocytopenia
drug interactions
guidelines for drug use
phenylthiohydantoin
enzalutamide
enzalutamide
phenylthiohydantoin
phenylthiohydantoin
phenylthiohydantoin
---
http://conseil-scientifique.public.lu/fr/publications/oncologie/enzalutamide-mise-a-jour-2018.html
2018
false
false
false
Luxembourg
French
guidelines for drug use
administration, oral
enzalutamide
enzalutamide
prostatic neoplasms
neoplasm metastasis
antineoplastic agents, hormonal
prostatic neoplasms, Castration-Resistant
survival analysis
adult
androgen antagonists
enzalutamide
phenylthiohydantoin
phenylthiohydantoin
---
https://www.has-sante.fr/portail/jcms/c_2867455/fr/xtandi
2018
false
false
false
false
France
French
evaluation of the transparency committee
enzalutamide
---
http://www.has-sante.fr/portail/jcms/c_2022075/fr/xtandi-enzalutamide-inhibiteur-de-la-voie-de-signalisation-des-recepteurs-aux-androgenes
http://www.has-sante.fr/portail/jcms/c_2022075/fr/xtandi
2015
false
false
false
France
French
guidelines for drug use
evaluation of the transparency committee
administration, oral
treatment outcome
antineoplastic agents, hormonal
antineoplastic agents, hormonal
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
enzalutamide
survival analysis
insurance, health, reimbursement
androgen antagonists
androgen antagonists
enzalutamide
enzalutamide
phenylthiohydantoin
phenylthiohydantoin
phenylthiohydantoin
---
http://www.meddispar.fr/Medicaments/XTANDI-40-B-112/(type)/letter/(value)/X/(cip)/3400927432484
2014
false
false
false
France
French
drug information
administration, oral
legislation, drug
drug prescriptions
enzalutamide
anti-androgens
antineoplastic agents, hormonal
enzalutamide
phenylthiohydantoin
phenylthiohydantoin
---
http://www.has-sante.fr/portail/jcms/c_1735878/fr/jevtana-xtandi-et-zytiga-cabazitaxel-enzalutamide-et-abiraterone-des-progres-therapeutiques-pour-certains-cancers-metastatiques-de-la-prostate-fiche-bum
2014
true
France
French
cabazitaxel
cabazitaxel
infusions, intravenous
neoplasm metastasis
prostatic neoplasms
antineoplastic agents
guidelines for drug use
administration, oral
enzalutamide
anti-androgens
androgen antagonists
antineoplastic agents, hormonal
abiraterone
steroid 17-alpha-hydroxylase
enzyme inhibitors
drug therapy, combination
survival analysis
phenylthiohydantoin
taxoids
Abiraterone Acetate
---
https://www.ema.europa.eu/medicines/human/EPAR/Xtandi
2013
false
United Kingdom
French
English
enzalutamide
enzalutamide
drug approval
europe
treatment outcome
administration, oral
prostatic neoplasms
neoplasm metastasis
summary of product characteristics
package leaflet
syndication feed
drug interactions
pregnancy
breast feeding
phenylthiohydantoin
antineoplastic agents
antineoplastic agents
survival analysis
drug evaluation, preclinical
---
Summary Basis of Decision (SBD) for Xtandi
Enzalutamide, 40 mg, capsule, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00202
2013
false
Canada
French
English
drug information
Product containing precisely enzalutamide 40 milligram/1 each conventional release
oral capsule (clinical drug)
administration, oral
drug approval
canada
enzalutamide
enzalutamide
neoplasm metastasis
prostatic neoplasms
antineoplastic agents
antineoplastic agents
treatment outcome
nonsteroidal Anti-Androgens
nonsteroidal Anti-Androgens
clinical trials, phase iii as topic
randomized controlled trials as topic
survival analysis
phenylthiohydantoin
---
http://www.has-sante.fr/portail/jcms/c_1710113/fr/xtandi
http://www.has-sante.fr/portail/jcms/c_1710112/fr/xtandi20112013avisct13108
2013
false
France
French
guidelines for drug use
evaluation of the transparency committee
administration, oral
adult
prostatic neoplasms
antineoplastic agents
antineoplastic agents
neoplasm metastasis
enzalutamide
enzalutamide
insurance, health, reimbursement
treatment outcome
anti-androgens
clinical trials, phase iii as topic
survival
phenylthiohydantoin
---
